Late-Breaking BIOTRONIK Study Results to Be Presented at ESC Congress 2017
CASTLE-AF Trial Investigates Hard Primary Outcomes of Catheter Ablation for Atrial Fibrillation in Heart Failure Patients for the First Time
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’s ESC Congress 2017.
The presentations and discussions will shed light on recent advances in the treatment of atrial fibrillation (AF) in heart failure patients, evaluate patients’ response to cardiac resynchronization therapy (CRT) and compare the safety and efficacy of drug-eluting stents (DES).
Held this year in Barcelona on August 26-30, the ESC Congress is the world’s largest cardiovascular congress, featuring more than 500 expert sessions. “BIOTRONIK is a recognized partner in supporting scientific research,” commented Manuel Ortega, Senior Vice President at BIOTRONIK. “At ESC Congress 2017, BIOTRONIK studies will contribute to the dialogue, reflecting on therapies that could have a significant impact on a variety of patient groups.”
1 CAUTION – Investigational device in the United States. Limited by US law to investigational use.
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.